USA • New York Stock Exchange • NYSE:QGEN • NL0015002SN0
The current stock price of QGEN is 50.78 USD. In the past month the price increased by 5.16%. In the past year, price increased by 21%.
ChartMill assigns a technical rating of 7 / 10 to QGEN. When comparing the yearly performance of all stocks, QGEN is one of the better performing stocks in the market, outperforming 73.36% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to QGEN. While QGEN has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 10.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.58% | ||
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| Debt/Equity | 0.45 |
24 analysts have analysed QGEN and the average price target is 54.71 USD. This implies a price increase of 7.74% is expected in the next year compared to the current price of 50.78.
For the next year, analysts expect an EPS growth of 8.94% and a revenue growth 6.28% for QGEN
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 22.03 | 205.423B | ||
| DHR | DANAHER CORP | 25.51 | 153.038B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 150.09 | 49.868B | ||
| A | AGILENT TECHNOLOGIES INC | 21.06 | 36.146B | ||
| IQV | IQVIA HOLDINGS INC | 14.73 | 32.812B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.87 | 28.211B | ||
| WAT | WATERS CORP | 22.68 | 19.534B | ||
| ILMN | ILLUMINA INC | 22.65 | 17.916B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.71 | 17.908B | ||
| MEDP | MEDPACE HOLDINGS INC | 31.55 | 14.94B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG 5912 NL
CEO: Thierry Bernard
Employees: 5700
Phone: 31773556600
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
The current stock price of QGEN is 50.78 USD. The price decreased by -0.33% in the last trading session.
QIAGEN N.V. (QGEN) has a dividend yield of 0.52%. The yearly dividend amount is currently 0.
QGEN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QGEN.
QIAGEN N.V. (QGEN) currently has 5700 employees.
QIAGEN N.V. (QGEN) will report earnings on 2026-05-05, after the market close.